-transparent.png){kind=logo}
Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.
Related Publications
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
June 1979,
Onkologie,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
April 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
October 1995,
Nucleic acids research,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
March 1979,
Cancer treatment reviews,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
September 2002,
Biochemistry,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
May 1996,
Environmental toxicology and pharmacology,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
January 1993,
Biochemistry,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
January 1991,
Postepy biochemii,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
January 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Rozencweig, and
D D von Hoff, and
M Slavik, and
F M Muggia
June 1978,
Harefuah,
